Follow-on drug yields positive bioequivalence results

07/11/2008 | Reuters

A 32-patient trial showed that INS-19, an experimental drug designed by Insmed to boost white blood cells, demonstrated equivalence with Amgen's Neupogen. Insmed plans to meet with the FDA to talk about a late-stage trial and thinks it is the first U.S. firm to report human-bioequivalence data for a follow-on biologic.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Compliance and Ethics Director
Sysmex America, Inc.
Lincolnshire, IL
Director, Site Quality Management
CareFusion
Palm Springs, CA
Compliance Officer-Medical Products
W. L. Gore
Flagstaff, AZ
Project Manager RA - 15000003MD
Abbott
Santa Clara, CA
Director, Site Quality Management
CareFusion
Minneapolis, MN